NCT06257771

Brief Summary

The goal of this observational study is to learn how the body processes ingested alcohol and how alcohol affects mood and blood sugar in both men and women after undergoing sleeve gastrectomy. The main question\[s\]it aims to answer are:

  • Are there differences in the way that ingested alcohol is handled in men versus women after sleeve gastrectomy?
  • What is the consequence of drinking alcohol on an empty stomach versus after a meal on blood sugar control after undergoing sleeve gastrectomy? Participants will participate in two types of alcohol tests (alcohol given orally or administered intravenously) after not eating anything overnight or after having a meal. Researchers will compare men and women who underwent sleeve gastrectomy with men and women who had no surgery, are of similar age and body composition, and have similar alcohol intake patterns.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
88

participants targeted

Target at P50-P75 for all trials

Timeline
27mo left

Started Jul 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress44%
Jul 2024Aug 2028

First Submitted

Initial submission to the registry

February 5, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 14, 2024

Completed
6 months until next milestone

Study Start

First participant enrolled

July 31, 2024

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2028

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2028

Last Updated

March 11, 2025

Status Verified

March 1, 2025

Enrollment Period

3.9 years

First QC Date

February 5, 2024

Last Update Submit

March 7, 2025

Conditions

Keywords

Alcohol metabolismBariatric surgeryHypoglycemiaMetabolic surgery

Outcome Measures

Primary Outcomes (3)

  • Blood alcohol concentrations (BAC)

    The concentration of alcohol measured in arterialized venous blood and estimated from breath )BrAC)

    From zero to up to 180 minutes post alcohol administration

  • Subjective effects of alcohol

    We will use valid psychometrically sound instruments to assess alcohol's subjective effects (e.g., stimulant and sedative effects of alcohol)

    Before and after (10-180 min) they consume the alcoholic beverage or receive the IV infusion for the alcohol clamp.

  • Plasma glucose concentrations

    The concentration of glucose measured in plasma.

    Before and after (10-180 min) they consume the alcoholic beverage.

Secondary Outcomes (1)

  • Gut hormones and other peptides

    Before and after (10-180 min) they consume the alcoholic beverage

Study Arms (4)

Women 1-5 years post-SG

* Alcohol orally administered (0.5 grams per kg of Fat-free mass) after overnight fast or after a standard meal * Alcohol administered IV using an alcohol clamp (target concentration of 0.6g/L after an overnight fast or one hour after consuming a standard mixed meal)

Drug: Alcohol (Ethanol)

Men 1-5 years post-SG

* Alcohol orally administered (0.5 grams per kg of Fat-free mass) after overnight fast or after a standard meal * Alcohol administered IV using an alcohol clamp (target concentration of 0.6g/L after an overnight fast or one hour after consuming a standard mixed meal)

Drug: Alcohol (Ethanol)

Women, non-operated control

* Alcohol orally administered (0.5 grams per kg of Fat-free mass) after overnight fast or after a standard meal * Alcohol administered IV using an alcohol clamp (target concentration of 0.6g/L after an overnight fast or one hour after consuming a standard mixed meal)

Drug: Alcohol (Ethanol)

Men, non-operated control

* Alcohol orally administered (0.5 grams per kg of Fat-free mass) after overnight fast or after a standard meal * Alcohol administered IV using an alcohol clamp (target concentration of 0.6g/L after an overnight fast or one hour after consuming a standard mixed meal)

Drug: Alcohol (Ethanol)

Interventions

Alcohol given orally (0.5 grams of alcohol per kg of fat-free mass) Alcohol given iv with a clamp ( 6% v/v alcohol prepared in 0.5% normal saline). The infusion rate will exponentially increase from the start of the infusion until the target BrAC of 0.6g/L (60mg%) is reached at 15 min, followed by an exponentially decreasing infusion rate, which will be tapered to a constant steady-state value to clamp the BrAC at the target value for a predetermined duration of 180 min.

Men 1-5 years post-SGMen, non-operated controlWomen 1-5 years post-SGWomen, non-operated control

Eligibility Criteria

Age21 Years - 64 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Carle Foundation Hospital and community sample

You may qualify if:

  • Surgery groups:
  • Male and female, 21-64 yrs. of age
  • Drink at least 1 standard drink per month but no more than 7 per week (women or \> 14 for men)
  • Underwent SG surgery 1-5 years ago
  • Non-surgery control group
  • Male and female who did not undergo bariatric surgery
  • Age , BMI, race , and alcohol pattern of consumption equivalent to participants in the SG surgery groups

You may not qualify if:

  • For all groups (surgery and non-surgery groups)
  • Smoking or having quit smoking less than 2 months ago
  • Pregnant or breastfeeding
  • Taking any medications that might affect alcohol metabolism
  • Anemia
  • Gastritis, colitis, Crohn's Disease, malabsorptive diseases, inflammatory diseases, liver disease, kidney disease, cancer less than five years ago, stroke, or severe organ dysfunction
  • Body weight \>450 pounds (because of a limit on body composition machine)
  • Alcohol use disorder
  • Regular use of drugs with addiction potential or regular misuse of substances
  • Abnormality on EKG as determined by a study physician to present a safety risk

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Illinois at Urbana Champaign

Urbana, Illinois, 61801, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Plasma samples

MeSH Terms

Conditions

Hypoglycemia

Interventions

Ethanol

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

AlcoholsOrganic Chemicals

Study Officials

  • Marta Y Pepino de Gruev, PhD

    University of Illinois at Urbana-Champaign

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mariel Molina-Castro, BS

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 5, 2024

First Posted

February 14, 2024

Study Start

July 31, 2024

Primary Completion (Estimated)

July 1, 2028

Study Completion (Estimated)

August 1, 2028

Last Updated

March 11, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will share

Data will be findable for the research community through NIAAADA. The research community will have access to data at the time of publication or when the award ends, whichever is sooner. NIAAADA will make decisions about how long to preserve the data.

Shared Documents
ICF
Time Frame
The research community will have access to data at the time of publication or when the award ends, whichever is sooner. NIAAADA will make decisions about how long to preserve the data.
Access Criteria
To request access of the data, researchers will use the standard processes at NIMH Data Archive (NDA) , and the NDA Data Access Committee will decide which requests to grant. The standard NDA data access process allows access for one year and is renewable

Locations